par Ladjeroud, Amel 
;Awada, Ahmad ;Bouzid, Kamel;Piccart-Gebhart, Martine
Référence Oncologie, 12, 7, page (422-431)
Publication Publié, 2010
;Awada, Ahmad ;Bouzid, Kamel;Piccart-Gebhart, Martine Référence Oncologie, 12, 7, page (422-431)
Publication Publié, 2010
Article révisé par les pairs
| Résumé : | Approximately 70-80% of breast cancers expressed estrogen receptors (ER). Endocrine therapy is the main pillar of the medical management of women with ER+ breast cancer. Since its use, endocrine treatment has radically changed the fate of breast cancer ER + with marked improvement of progression-free survival and overall survival. However, the benefits of the endocrine therapy are limited by the development of resistance. Experimental studies concluded that resistance to the endocrine therapy occurs at least in part via activation of several intracellular signal transduction pathways of cell proliferation. These observations have encouraged a number of phase II/III clinical trials evaluating different approaches of using the signal transduction inhibitors (STI) in combination with endocrine agents. These trials evaluated the feasibility and the capacity of these combinations to delay or to prevent endocrine resistance and are reviewed hereunder. © Springer-Verlag France 2010. |
